nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP1A1—liver cancer	0.271	1	CbGaD
Haloperidol—CBR1—Doxorubicin—liver cancer	0.211	0.381	CbGbCtD
Haloperidol—UGT1A9—Sorafenib—liver cancer	0.0877	0.158	CbGbCtD
Haloperidol—HTR2B—Sorafenib—liver cancer	0.0687	0.124	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0291	0.0526	CbGbCtD
Haloperidol—CYP3A7—Sorafenib—liver cancer	0.0291	0.0526	CbGbCtD
Haloperidol—CYP3A5—Sorafenib—liver cancer	0.0219	0.0394	CbGbCtD
Haloperidol—CYP2C19—Sorafenib—liver cancer	0.0176	0.0318	CbGbCtD
Haloperidol—CYP1A2—Sorafenib—liver cancer	0.0163	0.0293	CbGbCtD
Haloperidol—CYP2C9—Sorafenib—liver cancer	0.0147	0.0264	CbGbCtD
Haloperidol—ABCB1—Sorafenib—liver cancer	0.0142	0.0257	CbGbCtD
Haloperidol—CYP2D6—Sorafenib—liver cancer	0.0134	0.0242	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—liver cancer	0.00863	0.0156	CbGbCtD
Haloperidol—CYP3A4—Sorafenib—liver cancer	0.00852	0.0154	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—liver cancer	0.00813	0.0147	CbGbCtD
Haloperidol—CYP3A4—Doxorubicin—liver cancer	0.00517	0.00933	CbGbCtD
Haloperidol—Leukocytoclastic vasculitis—Sorafenib—liver cancer	0.0021	0.0348	CcSEcCtD
Haloperidol—Endocrine disorder—Sorafenib—liver cancer	0.00124	0.0206	CcSEcCtD
Haloperidol—Gynaecomastia—Sorafenib—liver cancer	0.000919	0.0153	CcSEcCtD
Haloperidol—Hepatic function abnormal—Sorafenib—liver cancer	0.000854	0.0142	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Sorafenib—liver cancer	0.000791	0.0131	CcSEcCtD
Haloperidol—Hyponatraemia—Sorafenib—liver cancer	0.000749	0.0124	CcSEcCtD
Haloperidol—Body temperature decreased—Epirubicin—liver cancer	0.000677	0.0113	CcSEcCtD
Haloperidol—Hypothermia—Epirubicin—liver cancer	0.000677	0.0113	CcSEcCtD
Haloperidol—Breast disorder—Sorafenib—liver cancer	0.000674	0.0112	CcSEcCtD
Haloperidol—Dysphagia—Sorafenib—liver cancer	0.000645	0.0107	CcSEcCtD
Haloperidol—Hypothermia—Doxorubicin—liver cancer	0.000627	0.0104	CcSEcCtD
Haloperidol—Body temperature decreased—Doxorubicin—liver cancer	0.000627	0.0104	CcSEcCtD
Haloperidol—Neutropenia—Sorafenib—liver cancer	0.000603	0.01	CcSEcCtD
Haloperidol—Erectile dysfunction—Sorafenib—liver cancer	0.000594	0.00987	CcSEcCtD
Haloperidol—Weight decreased—Sorafenib—liver cancer	0.000583	0.00969	CcSEcCtD
Haloperidol—Hypokinesia—Epirubicin—liver cancer	0.000563	0.00935	CcSEcCtD
Haloperidol—Jaundice—Sorafenib—liver cancer	0.00056	0.00931	CcSEcCtD
Haloperidol—Hepatobiliary disease—Sorafenib—liver cancer	0.000544	0.00903	CcSEcCtD
Haloperidol—Nystagmus—Epirubicin—liver cancer	0.000532	0.00883	CcSEcCtD
Haloperidol—Hypokinesia—Doxorubicin—liver cancer	0.000521	0.00865	CcSEcCtD
Haloperidol—Ventricular arrhythmia—Epirubicin—liver cancer	0.000513	0.00853	CcSEcCtD
Haloperidol—Urinary tract disorder—Sorafenib—liver cancer	0.00051	0.00847	CcSEcCtD
Haloperidol—Connective tissue disorder—Sorafenib—liver cancer	0.000507	0.00843	CcSEcCtD
Haloperidol—Urethral disorder—Sorafenib—liver cancer	0.000506	0.00841	CcSEcCtD
Haloperidol—Nystagmus—Doxorubicin—liver cancer	0.000492	0.00817	CcSEcCtD
Haloperidol—Cardiac disorder—Sorafenib—liver cancer	0.000479	0.00796	CcSEcCtD
Haloperidol—Ventricular arrhythmia—Doxorubicin—liver cancer	0.000475	0.00789	CcSEcCtD
Haloperidol—Angiopathy—Sorafenib—liver cancer	0.000468	0.00778	CcSEcCtD
Haloperidol—Immune system disorder—Sorafenib—liver cancer	0.000466	0.00775	CcSEcCtD
Haloperidol—Mediastinal disorder—Sorafenib—liver cancer	0.000465	0.00773	CcSEcCtD
Haloperidol—Alopecia—Sorafenib—liver cancer	0.000456	0.00758	CcSEcCtD
Haloperidol—Mental disorder—Sorafenib—liver cancer	0.000452	0.00751	CcSEcCtD
Haloperidol—Malnutrition—Sorafenib—liver cancer	0.000449	0.00746	CcSEcCtD
Haloperidol—Breast pain—Epirubicin—liver cancer	0.000435	0.00723	CcSEcCtD
Haloperidol—Amenorrhoea—Epirubicin—liver cancer	0.000432	0.00718	CcSEcCtD
Haloperidol—Muscle spasms—Sorafenib—liver cancer	0.000432	0.00718	CcSEcCtD
Haloperidol—Anaemia—Sorafenib—liver cancer	0.000415	0.0069	CcSEcCtD
Haloperidol—Dyskinesia—Epirubicin—liver cancer	0.000404	0.00671	CcSEcCtD
Haloperidol—Breast pain—Doxorubicin—liver cancer	0.000403	0.00669	CcSEcCtD
Haloperidol—Leukopenia—Sorafenib—liver cancer	0.000402	0.00668	CcSEcCtD
Haloperidol—Amenorrhoea—Doxorubicin—liver cancer	0.0004	0.00665	CcSEcCtD
Haloperidol—Gait disturbance—Epirubicin—liver cancer	0.000389	0.00647	CcSEcCtD
Haloperidol—Hypertension—Sorafenib—liver cancer	0.000388	0.00644	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00038	0.00631	CcSEcCtD
Haloperidol—Ventricular tachycardia—Epirubicin—liver cancer	0.00038	0.00631	CcSEcCtD
Haloperidol—Injection site reaction—Epirubicin—liver cancer	0.000378	0.00627	CcSEcCtD
Haloperidol—Dry mouth—Sorafenib—liver cancer	0.000374	0.00622	CcSEcCtD
Haloperidol—Dyskinesia—Doxorubicin—liver cancer	0.000374	0.00621	CcSEcCtD
Haloperidol—Salivary hypersecretion—Epirubicin—liver cancer	0.000369	0.00613	CcSEcCtD
Haloperidol—Anaphylactic shock—Sorafenib—liver cancer	0.000367	0.00609	CcSEcCtD
Haloperidol—Gait disturbance—Doxorubicin—liver cancer	0.00036	0.00598	CcSEcCtD
Haloperidol—Nervous system disorder—Sorafenib—liver cancer	0.00036	0.00597	CcSEcCtD
Haloperidol—Thrombocytopenia—Sorafenib—liver cancer	0.000359	0.00596	CcSEcCtD
Haloperidol—Skin disorder—Sorafenib—liver cancer	0.000356	0.00592	CcSEcCtD
Haloperidol—Ventricular tachycardia—Doxorubicin—liver cancer	0.000351	0.00584	CcSEcCtD
Haloperidol—Anorexia—Sorafenib—liver cancer	0.000349	0.00581	CcSEcCtD
Haloperidol—Injection site reaction—Doxorubicin—liver cancer	0.000349	0.0058	CcSEcCtD
Haloperidol—Salivary hypersecretion—Doxorubicin—liver cancer	0.000341	0.00567	CcSEcCtD
Haloperidol—Hypertonia—Epirubicin—liver cancer	0.000333	0.00553	CcSEcCtD
Haloperidol—Dyspnoea—Sorafenib—liver cancer	0.000327	0.00543	CcSEcCtD
Haloperidol—Dyspepsia—Sorafenib—liver cancer	0.000323	0.00536	CcSEcCtD
Haloperidol—Decreased appetite—Sorafenib—liver cancer	0.000319	0.0053	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Sorafenib—liver cancer	0.000317	0.00526	CcSEcCtD
Haloperidol—Hepatic function abnormal—Epirubicin—liver cancer	0.000315	0.00524	CcSEcCtD
Haloperidol—Photosensitivity—Epirubicin—liver cancer	0.000314	0.00522	CcSEcCtD
Haloperidol—Constipation—Sorafenib—liver cancer	0.000314	0.00521	CcSEcCtD
Haloperidol—Hypertonia—Doxorubicin—liver cancer	0.000308	0.00512	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Epirubicin—liver cancer	0.000292	0.00485	CcSEcCtD
Haloperidol—Hepatic function abnormal—Doxorubicin—liver cancer	0.000292	0.00485	CcSEcCtD
Haloperidol—Urticaria—Sorafenib—liver cancer	0.000291	0.00484	CcSEcCtD
Haloperidol—Photosensitivity—Doxorubicin—liver cancer	0.000291	0.00483	CcSEcCtD
Haloperidol—Body temperature increased—Sorafenib—liver cancer	0.00029	0.00482	CcSEcCtD
Haloperidol—Hypoglycaemia—Epirubicin—liver cancer	0.000282	0.00469	CcSEcCtD
Haloperidol—Lethargy—Epirubicin—liver cancer	0.000281	0.00467	CcSEcCtD
Haloperidol—Hyponatraemia—Epirubicin—liver cancer	0.000277	0.0046	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00027	0.00449	CcSEcCtD
Haloperidol—Hypersensitivity—Sorafenib—liver cancer	0.00027	0.00449	CcSEcCtD
Haloperidol—Face oedema—Epirubicin—liver cancer	0.000266	0.00442	CcSEcCtD
Haloperidol—Cardiac arrest—Epirubicin—liver cancer	0.000262	0.00436	CcSEcCtD
Haloperidol—Hypoglycaemia—Doxorubicin—liver cancer	0.000261	0.00434	CcSEcCtD
Haloperidol—Lethargy—Doxorubicin—liver cancer	0.00026	0.00433	CcSEcCtD
Haloperidol—Pruritus—Sorafenib—liver cancer	0.000259	0.00431	CcSEcCtD
Haloperidol—Hyponatraemia—Doxorubicin—liver cancer	0.000256	0.00426	CcSEcCtD
Haloperidol—Liver function test abnormal—Epirubicin—liver cancer	0.000255	0.00423	CcSEcCtD
Haloperidol—Orthostatic hypotension—Epirubicin—liver cancer	0.000252	0.00418	CcSEcCtD
Haloperidol—Diarrhoea—Sorafenib—liver cancer	0.000251	0.00417	CcSEcCtD
Haloperidol—Breast disorder—Epirubicin—liver cancer	0.000249	0.00414	CcSEcCtD
Haloperidol—Face oedema—Doxorubicin—liver cancer	0.000246	0.00409	CcSEcCtD
Haloperidol—Cardiac arrest—Doxorubicin—liver cancer	0.000243	0.00403	CcSEcCtD
Haloperidol—Dizziness—Sorafenib—liver cancer	0.000242	0.00403	CcSEcCtD
Haloperidol—Dysphagia—Epirubicin—liver cancer	0.000238	0.00396	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—liver cancer	0.000236	0.00391	CcSEcCtD
Haloperidol—Vomiting—Sorafenib—liver cancer	0.000233	0.00387	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—liver cancer	0.000233	0.00387	CcSEcCtD
Haloperidol—Rash—Sorafenib—liver cancer	0.000231	0.00384	CcSEcCtD
Haloperidol—Dermatitis—Sorafenib—liver cancer	0.000231	0.00384	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—liver cancer	0.000231	0.00383	CcSEcCtD
Haloperidol—Headache—Sorafenib—liver cancer	0.00023	0.00382	CcSEcCtD
Haloperidol—Pancytopenia—Epirubicin—liver cancer	0.000226	0.00376	CcSEcCtD
Haloperidol—Neutropenia—Epirubicin—liver cancer	0.000223	0.0037	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—liver cancer	0.00022	0.00366	CcSEcCtD
Haloperidol—Nausea—Sorafenib—liver cancer	0.000218	0.00362	CcSEcCtD
Haloperidol—Photosensitivity reaction—Epirubicin—liver cancer	0.000217	0.00361	CcSEcCtD
Haloperidol—Weight increased—Epirubicin—liver cancer	0.000217	0.0036	CcSEcCtD
Haloperidol—Weight decreased—Epirubicin—liver cancer	0.000216	0.00358	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—liver cancer	0.000215	0.00357	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—liver cancer	0.000212	0.00353	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—liver cancer	0.000209	0.00348	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—liver cancer	0.000207	0.00344	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—liver cancer	0.000206	0.00343	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—liver cancer	0.000201	0.00334	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—liver cancer	0.000201	0.00334	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—liver cancer	0.000201	0.00333	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—liver cancer	0.000199	0.00331	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—liver cancer	0.000199	0.0033	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—liver cancer	0.000198	0.00329	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—liver cancer	0.000197	0.00327	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—liver cancer	0.000192	0.00318	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—liver cancer	0.000191	0.00317	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—liver cancer	0.000188	0.00313	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—liver cancer	0.000187	0.00311	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—liver cancer	0.000187	0.00311	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—liver cancer	0.000186	0.00309	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—liver cancer	0.000184	0.00305	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—liver cancer	0.000183	0.00305	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—liver cancer	0.000178	0.00296	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—liver cancer	0.000177	0.00294	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—liver cancer	0.000176	0.00293	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—liver cancer	0.000174	0.0029	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—liver cancer	0.000173	0.00288	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—liver cancer	0.000173	0.00288	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—liver cancer	0.000173	0.00287	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—liver cancer	0.000172	0.00286	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—liver cancer	0.000172	0.00286	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—liver cancer	0.00017	0.00283	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—liver cancer	0.000169	0.0028	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—liver cancer	0.000167	0.00278	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—liver cancer	0.000166	0.00276	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—liver cancer	0.000165	0.00274	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—liver cancer	0.000164	0.00272	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—liver cancer	0.00016	0.00266	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—liver cancer	0.00016	0.00265	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—liver cancer	0.000159	0.00265	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—liver cancer	0.000159	0.00264	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—liver cancer	0.000156	0.0026	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—liver cancer	0.000156	0.00259	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—liver cancer	0.000155	0.00257	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—liver cancer	0.000154	0.00255	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—liver cancer	0.000153	0.00255	CcSEcCtD
Haloperidol—Agitation—Epirubicin—liver cancer	0.000153	0.00254	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—liver cancer	0.000149	0.00248	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—liver cancer	0.000149	0.00247	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—liver cancer	0.000148	0.00245	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—liver cancer	0.000145	0.00241	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—liver cancer	0.000144	0.00239	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—liver cancer	0.000143	0.00238	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—liver cancer	0.000142	0.00236	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—liver cancer	0.000141	0.00235	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—liver cancer	0.000141	0.00234	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00014	0.00233	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—liver cancer	0.000138	0.0023	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—liver cancer	0.000138	0.00229	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—liver cancer	0.000138	0.00228	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—liver cancer	0.000137	0.00227	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—liver cancer	0.000135	0.00225	CcSEcCtD
Haloperidol—Oedema—Epirubicin—liver cancer	0.000135	0.00225	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—liver cancer	0.000133	0.00221	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—liver cancer	0.000133	0.00221	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—liver cancer	0.000133	0.0022	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—liver cancer	0.000133	0.0022	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—liver cancer	0.000132	0.0022	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—liver cancer	0.000132	0.00219	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—liver cancer	0.000131	0.00218	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—liver cancer	0.00013	0.00217	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00013	0.00216	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—liver cancer	0.000129	0.00215	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—liver cancer	0.000128	0.00213	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—liver cancer	0.000127	0.0021	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—liver cancer	0.000126	0.0021	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—liver cancer	0.000125	0.00208	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—liver cancer	0.000125	0.00208	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—liver cancer	0.000123	0.00204	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—liver cancer	0.000123	0.00204	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—liver cancer	0.000123	0.00204	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—liver cancer	0.000122	0.00203	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—liver cancer	0.000122	0.00202	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—liver cancer	0.000121	0.00201	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—liver cancer	0.000121	0.00201	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—liver cancer	0.00012	0.002	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—liver cancer	0.00012	0.00199	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—liver cancer	0.000119	0.00198	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—liver cancer	0.000118	0.00196	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—liver cancer	0.000117	0.00195	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—liver cancer	0.000117	0.00194	CcSEcCtD
Haloperidol—Constipation—Epirubicin—liver cancer	0.000116	0.00193	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—liver cancer	0.000113	0.00188	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—liver cancer	0.000112	0.00186	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—liver cancer	0.000112	0.00186	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—liver cancer	0.000111	0.00185	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—liver cancer	0.00011	0.00183	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—liver cancer	0.000109	0.00181	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000108	0.0018	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—liver cancer	0.000108	0.00179	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—liver cancer	0.000107	0.00178	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—liver cancer	0.000107	0.00178	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—liver cancer	0.000103	0.00172	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—liver cancer	9.98e-05	0.00166	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—liver cancer	9.96e-05	0.00165	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—liver cancer	9.91e-05	0.00165	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—liver cancer	9.59e-05	0.00159	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—liver cancer	9.27e-05	0.00154	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—liver cancer	9.24e-05	0.00153	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—liver cancer	8.96e-05	0.00149	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—liver cancer	8.87e-05	0.00147	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—liver cancer	8.62e-05	0.00143	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—liver cancer	8.58e-05	0.00143	CcSEcCtD
Haloperidol—Rash—Epirubicin—liver cancer	8.54e-05	0.00142	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—liver cancer	8.54e-05	0.00142	CcSEcCtD
Haloperidol—Headache—Epirubicin—liver cancer	8.49e-05	0.00141	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—liver cancer	8.29e-05	0.00138	CcSEcCtD
Haloperidol—Nausea—Epirubicin—liver cancer	8.05e-05	0.00134	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—liver cancer	7.97e-05	0.00132	CcSEcCtD
Haloperidol—Rash—Doxorubicin—liver cancer	7.9e-05	0.00131	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—liver cancer	7.9e-05	0.00131	CcSEcCtD
Haloperidol—Headache—Doxorubicin—liver cancer	7.85e-05	0.00131	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—liver cancer	7.45e-05	0.00124	CcSEcCtD
Haloperidol—DRD3—Signaling Pathways—CCND1—liver cancer	4.16e-06	3.63e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—JUN—liver cancer	4.15e-06	3.62e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PPARG—liver cancer	4.15e-06	3.62e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—liver cancer	4.15e-06	3.62e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP1A1—liver cancer	4.14e-06	3.61e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CTNNB1—liver cancer	4.12e-06	3.59e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PSMA4—liver cancer	4.11e-06	3.59e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PSMD10—liver cancer	4.11e-06	3.59e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARA—liver cancer	4.11e-06	3.59e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—STAT3—liver cancer	4.11e-06	3.58e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP1A1—liver cancer	4.1e-06	3.57e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—liver cancer	4.1e-06	3.57e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—MTHFR—liver cancer	4.09e-06	3.57e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—liver cancer	4.09e-06	3.56e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CD—liver cancer	4.08e-06	3.56e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CDKN1A—liver cancer	4.08e-06	3.56e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—STAT3—liver cancer	4.05e-06	3.53e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—PIK3CA—liver cancer	4.04e-06	3.52e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—liver cancer	4.04e-06	3.52e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SERPINE1—liver cancer	4.04e-06	3.52e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CDKN1A—liver cancer	4.03e-06	3.51e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTP1—liver cancer	4.02e-06	3.51e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CD—liver cancer	4.02e-06	3.5e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARA—liver cancer	4.01e-06	3.5e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CD—liver cancer	4.01e-06	3.49e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CD—liver cancer	4e-06	3.49e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GOT2—liver cancer	4e-06	3.49e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—KRAS—liver cancer	4e-06	3.48e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK8—liver cancer	3.98e-06	3.47e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	3.98e-06	3.47e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—AKT1—liver cancer	3.97e-06	3.46e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SERPINE1—liver cancer	3.97e-06	3.46e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—PIK3CA—liver cancer	3.97e-06	3.46e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—HMOX1—liver cancer	3.97e-06	3.46e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SERPINE1—liver cancer	3.96e-06	3.46e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ALB—liver cancer	3.95e-06	3.45e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—KRAS—liver cancer	3.93e-06	3.43e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK8—liver cancer	3.93e-06	3.43e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—KRAS—liver cancer	3.92e-06	3.42e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—AKT1—liver cancer	3.92e-06	3.42e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MYC—liver cancer	3.9e-06	3.4e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—liver cancer	3.9e-06	3.4e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TGFB1—liver cancer	3.89e-06	3.39e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—STAT3—liver cancer	3.86e-06	3.37e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—MTHFR—liver cancer	3.86e-06	3.36e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MTHFR—liver cancer	3.82e-06	3.33e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MYC—liver cancer	3.82e-06	3.33e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TGFB1—liver cancer	3.81e-06	3.32e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CD—liver cancer	3.78e-06	3.3e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARA—liver cancer	3.78e-06	3.3e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP2E1—liver cancer	3.76e-06	3.28e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MYC—liver cancer	3.76e-06	3.28e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TGFB1—liver cancer	3.75e-06	3.27e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARA—liver cancer	3.75e-06	3.27e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ALB—liver cancer	3.73e-06	3.26e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTM1—liver cancer	3.7e-06	3.22e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.69e-06	3.22e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—liver cancer	3.68e-06	3.21e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PIK3CA—liver cancer	3.67e-06	3.2e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RAF1—liver cancer	3.64e-06	3.18e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—liver cancer	3.64e-06	3.17e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—liver cancer	3.63e-06	3.16e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	3.61e-06	3.15e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—liver cancer	3.6e-06	3.14e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—liver cancer	3.6e-06	3.14e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—liver cancer	3.59e-06	3.13e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—liver cancer	3.59e-06	3.13e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RAF1—liver cancer	3.59e-06	3.13e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFB1—liver cancer	3.58e-06	3.12e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RAF1—liver cancer	3.58e-06	3.12e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MTOR—liver cancer	3.56e-06	3.1e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CB—liver cancer	3.56e-06	3.1e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—liver cancer	3.53e-06	3.08e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CG—liver cancer	3.52e-06	3.07e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYCS—liver cancer	3.52e-06	3.07e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP1A1—liver cancer	3.5e-06	3.05e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MTOR—liver cancer	3.5e-06	3.05e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CB—liver cancer	3.5e-06	3.05e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—liver cancer	3.5e-06	3.05e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CB—liver cancer	3.49e-06	3.05e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MTOR—liver cancer	3.49e-06	3.05e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CB—liver cancer	3.49e-06	3.04e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—liver cancer	3.47e-06	3.03e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GGT1—liver cancer	3.46e-06	3.01e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GOT1—liver cancer	3.46e-06	3.01e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CG—liver cancer	3.44e-06	3e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARG—liver cancer	3.4e-06	2.96e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—liver cancer	3.4e-06	2.96e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—liver cancer	3.38e-06	2.95e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFB1—liver cancer	3.38e-06	2.94e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.37e-06	2.94e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—liver cancer	3.34e-06	2.91e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1B—liver cancer	3.34e-06	2.91e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—liver cancer	3.34e-06	2.91e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—liver cancer	3.34e-06	2.91e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFB1—liver cancer	3.33e-06	2.9e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARG—liver cancer	3.32e-06	2.89e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—liver cancer	3.32e-06	2.89e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—liver cancer	3.31e-06	2.89e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—liver cancer	3.3e-06	2.88e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CB—liver cancer	3.3e-06	2.87e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1B—liver cancer	3.29e-06	2.86e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1B—liver cancer	3.28e-06	2.86e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CASP3—liver cancer	3.27e-06	2.85e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—liver cancer	3.27e-06	2.85e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MTHFR—liver cancer	3.27e-06	2.85e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—liver cancer	3.25e-06	2.83e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—liver cancer	3.25e-06	2.83e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—liver cancer	3.24e-06	2.83e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—liver cancer	3.24e-06	2.83e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CG—liver cancer	3.24e-06	2.82e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CASP3—liver cancer	3.22e-06	2.81e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—liver cancer	3.21e-06	2.8e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CASP3—liver cancer	3.21e-06	2.8e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CG—liver cancer	3.21e-06	2.8e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—liver cancer	3.21e-06	2.8e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARA—liver cancer	3.2e-06	2.79e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—liver cancer	3.2e-06	2.79e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—liver cancer	3.2e-06	2.79e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—liver cancer	3.19e-06	2.78e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—liver cancer	3.19e-06	2.78e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—liver cancer	3.19e-06	2.78e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—JUN—liver cancer	3.18e-06	2.77e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CTNNB1—liver cancer	3.15e-06	2.75e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—liver cancer	3.14e-06	2.73e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—liver cancer	3.13e-06	2.73e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—JUN—liver cancer	3.13e-06	2.73e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—liver cancer	3.13e-06	2.73e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—liver cancer	3.13e-06	2.73e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARG—liver cancer	3.13e-06	2.73e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—JUN—liver cancer	3.12e-06	2.72e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CTNNB1—liver cancer	3.1e-06	2.71e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—liver cancer	3.1e-06	2.71e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARG—liver cancer	3.1e-06	2.7e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CTNNB1—liver cancer	3.1e-06	2.7e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CD—liver cancer	3.1e-06	2.7e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—liver cancer	3.09e-06	2.7e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—liver cancer	3.09e-06	2.69e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—liver cancer	3.09e-06	2.69e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1A—liver cancer	3.08e-06	2.69e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—liver cancer	3.06e-06	2.67e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HMOX1—liver cancer	3.06e-06	2.67e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ALB—liver cancer	3.06e-06	2.66e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—liver cancer	3.05e-06	2.66e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—liver cancer	3.04e-06	2.65e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—liver cancer	3.04e-06	2.65e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1A—liver cancer	3.03e-06	2.64e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1A—liver cancer	3.03e-06	2.64e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CD—liver cancer	3.02e-06	2.63e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK8—liver cancer	3.01e-06	2.62e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—liver cancer	3e-06	2.62e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—liver cancer	3e-06	2.61e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ALB—liver cancer	2.98e-06	2.6e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK8—liver cancer	2.96e-06	2.58e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK8—liver cancer	2.95e-06	2.57e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—liver cancer	2.95e-06	2.57e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—liver cancer	2.95e-06	2.57e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—liver cancer	2.95e-06	2.57e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—liver cancer	2.94e-06	2.57e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—liver cancer	2.94e-06	2.57e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—liver cancer	2.93e-06	2.56e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.88e-06	2.51e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—liver cancer	2.87e-06	2.5e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—liver cancer	2.87e-06	2.5e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—liver cancer	2.86e-06	2.49e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTM1—liver cancer	2.85e-06	2.49e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CD—liver cancer	2.85e-06	2.48e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—liver cancer	2.83e-06	2.47e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—liver cancer	2.83e-06	2.46e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CD—liver cancer	2.82e-06	2.46e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—liver cancer	2.82e-06	2.46e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ALB—liver cancer	2.81e-06	2.45e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ALB—liver cancer	2.79e-06	2.43e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—liver cancer	2.78e-06	2.42e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—liver cancer	2.78e-06	2.42e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—liver cancer	2.75e-06	2.4e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CG—liver cancer	2.74e-06	2.39e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—liver cancer	2.74e-06	2.39e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—liver cancer	2.73e-06	2.38e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—liver cancer	2.73e-06	2.38e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—liver cancer	2.71e-06	2.36e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—liver cancer	2.71e-06	2.36e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1A1—liver cancer	2.7e-06	2.36e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—liver cancer	2.7e-06	2.35e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CB—liver cancer	2.7e-06	2.35e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—liver cancer	2.7e-06	2.35e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—liver cancer	2.66e-06	2.32e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—liver cancer	2.65e-06	2.31e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARG—liver cancer	2.65e-06	2.31e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CB—liver cancer	2.63e-06	2.3e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—liver cancer	2.62e-06	2.29e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—liver cancer	2.61e-06	2.27e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—liver cancer	2.55e-06	2.23e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFB1—liver cancer	2.55e-06	2.22e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—liver cancer	2.54e-06	2.22e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MTHFR—liver cancer	2.52e-06	2.2e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—liver cancer	2.51e-06	2.19e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—liver cancer	2.51e-06	2.19e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—liver cancer	2.51e-06	2.19e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFB1—liver cancer	2.51e-06	2.19e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFB1—liver cancer	2.5e-06	2.18e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—liver cancer	2.49e-06	2.17e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CB—liver cancer	2.48e-06	2.16e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARA—liver cancer	2.47e-06	2.16e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CB—liver cancer	2.46e-06	2.15e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CD—liver cancer	2.41e-06	2.1e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—liver cancer	2.4e-06	2.1e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ALB—liver cancer	2.38e-06	2.08e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—liver cancer	2.36e-06	2.06e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—liver cancer	2.35e-06	2.05e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—liver cancer	2.32e-06	2.03e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—liver cancer	2.32e-06	2.02e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—liver cancer	2.32e-06	2.02e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—liver cancer	2.17e-06	1.89e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—liver cancer	2.13e-06	1.86e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—liver cancer	2.13e-06	1.86e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—liver cancer	2.13e-06	1.86e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CG—liver cancer	2.12e-06	1.85e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CB—liver cancer	2.1e-06	1.83e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—liver cancer	2.1e-06	1.83e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—liver cancer	2.06e-06	1.8e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—liver cancer	2.06e-06	1.8e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARG—liver cancer	2.04e-06	1.78e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—liver cancer	2.01e-06	1.75e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—liver cancer	2.01e-06	1.75e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—liver cancer	1.97e-06	1.72e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—liver cancer	1.97e-06	1.72e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—liver cancer	1.92e-06	1.67e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—liver cancer	1.89e-06	1.65e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—liver cancer	1.89e-06	1.64e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CD—liver cancer	1.86e-06	1.62e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALB—liver cancer	1.84e-06	1.6e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—liver cancer	1.77e-06	1.54e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—liver cancer	1.74e-06	1.52e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—liver cancer	1.74e-06	1.52e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—liver cancer	1.74e-06	1.52e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—liver cancer	1.64e-06	1.43e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—liver cancer	1.64e-06	1.43e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CB—liver cancer	1.62e-06	1.41e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—liver cancer	1.61e-06	1.4e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—liver cancer	1.51e-06	1.32e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—liver cancer	1.5e-06	1.31e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—liver cancer	1.34e-06	1.17e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—liver cancer	1.31e-06	1.14e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—liver cancer	1.28e-06	1.12e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—liver cancer	1.24e-06	1.08e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—liver cancer	1.23e-06	1.07e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—liver cancer	1.05e-06	9.13e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—liver cancer	9.89e-07	8.62e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—liver cancer	8.08e-07	7.05e-06	CbGpPWpGaD
